来凯医药(2105.HK)发布2024年度业绩:核心临床研究快于预期 加强全球化合作

格隆汇
25 Mar

来凯医药(2105.HK)发布2024年度业绩,展示公司在高效推进临床及临床前候选药物开发,及全球化合作方面取得的重大进展。“就在2024全年业绩公布之际,中国刚刚宣布推进‘体重管理年’3年行动,为提升全民健康做出了重要指引,也为新一代减肥疗法的研发带来巨大机遇。”来凯医药董事会主席吕向阳博士表示:来凯医药正在全速推进兼具增肌减脂潜力的LAE102中美临床试验,与礼来的临床合作印证了该产品具有国际...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10